Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, announced a $5 billion Series C on November 17. Greenoaks and Sequoia Capital co-led the round, with a16z and other new investors, continued significant investment from Alphabet, and participation from all existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The money will mature its in-house drug design engine IsoDDE, push into new biology, build global AI-led bioengineering infrastructure and move oncology and immunology candidates toward clinical trials. CEO Demis Hassabis announced it himself on X. No valuation was disclosed.
Key Takeaways
- ✓Size and investors: a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with a16z and other new investors, continued significant investment from Alphabet and all existing investors; the round was oversubscribed and no valuation was disclosed
- ✓Core asset IsoDDE: it unifies a suite of foundational simulation AI models that work across therapeutic areas and drug modalities, combined with proprietary agents that reason over complex biological systems to design molecules
- ✓Progress: the company says internal oncology and immunology programs and partnered programs are showing positive preclinical results, setting the stage for clinical entry
- ✓Use of funds: maturing IsoDDE, building a partner ecosystem for mechanistic disease biology, global AI-led bioengineering infrastructure, and AI-first translational and clinical development capacity
- ✓Demis Hassabis wrote on X that the mission is to solve all disease by reimagining drug design from first principles with AI and radically cutting the time and cost to find new medicines

Key Decision Metrics at a Glance
Turn your technical choice into a development budget
Compare 40 dev plans & simulate token costs vs $20/mo subscriptions
Project Links & Resources
Direct AccessIn-Depth Technical Analysis
Background
Traditional drug discovery runs through repeated design, make and test cycles, and going from a first hit to a clinical candidate often takes years. Isomorphic Labs was spun out of Google DeepMind in 2021 to turn that into repeatable engineering with AI. On November 17 it announced a $5 billion Series C, co-led by Greenoaks and Sequoia Capital, with a16z and other new investors, continued significant investment from Alphabet, and every existing investor joining.
How it works
The company is built around its in-house drug design engine, IsoDDE. The release says it unifies a suite of foundational simulation AI models that work across therapeutic areas and drug modalities, paired with proprietary agents that reason over complex biological systems and search vast chemical spaces to design molecules. A September company post gave an example: the design agent running autonomously for 2 to 4 days covers a molecule optimization path where each step traditionally takes 1 to 3 months.
Numbers that matter
No new benchmark results and no valuation were disclosed. The company only says its internal oncology and immunology programs and partnered programs are showing positive preclinical results, setting the stage for clinical entry.
What it means for developers
IsoDDE is not offered externally, so developers cannot call it. The significance is that a leading AI for science company now has funding on the scale of frontier model labs, which should speed up clinical tests of the model plus agent approach to molecule design. Teams working on computational biology or science agents should watch closely.
Benchmark side-by-side against alternatives, or calculate monthly token cost vs subscription break-even.
Discussion & Comments
0Sign in to join the discussion
Connect with AI developers to exchange benchmark insights.